Efficacy of cognitive bias modification interventions in anxiety and depressive disorders:a systematic review and network meta-analysis by Fodor, Liviu A. et al.
VU Research Portal
Efficacy of cognitive bias modification interventions in anxiety and depressive
disorders
Fodor, Liviu A.; Georgescu, Raluca; Cuijpers, Pim; Szamoskozi, tefan; David, Daniel;




DOI (link to publisher)
10.1016/S2215-0366(20)30130-9
document version
Publisher's PDF, also known as Version of record
document license
Article 25fa Dutch Copyright Act
Link to publication in VU Research Portal
citation for published version (APA)
Fodor, L. A., Georgescu, R., Cuijpers, P., Szamoskozi, ., David, D., Furukawa, T. A., & Cristea, I. A. (2020).
Efficacy of cognitive bias modification interventions in anxiety and depressive disorders: a systematic review and
network meta-analysis. The Lancet. Psychiatry, 7(6), 506-514. https://doi.org/10.1016/S2215-0366(20)30130-9
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
E-mail address:
vuresearchportal.ub@vu.nl
Download date: 22. May. 2021
506 www.thelancet.com/psychiatry   Vol 7   June 2020
Articles
Lancet Psychiatry 2020; 
7: 506–14
See Comment page 465
*Contributed equally
International Institute for 
The Advanced Studies of 
Psychotherapy and Applied 
Mental Health (L A Fodor MA, 
R Georgescu MA), Evidence 
Based Psychological 
Assessment and Interventions 
Doctoral School (L A Fodor, 
R Georgescu), Department of 
Applied Psychology 
(Prof Ș Szamoskozi PhD), and 
Department of Clinical 
Psychology and Psychotherapy 
(Prof D David PhD, 
I A Cristea PhD), Babeș-Bolyai 
University, Cluj-Napoca, 
Romania; Department of 
Clinical, Neuro and 
Developmental Psychology, 
Amsterdam Public Health 
Research Institute, Vrije 
Universiteit Amsterdam, 
Amsterdam, Netherlands 
(Prof P Cuijpers PhD); 
Department of Oncological 
Sciences, Icahn School of 
Medicine at Mount Sinai, 
New York, NY, USA 
(Prof D David); Department of 
Health Promotion and Human 
Behavior, School of Public 
Health in the Graduate School 
of Medicine, Kyoto University, 
Kyoto, Japan 
(Prof T A Furukawa MD); and 
Department of Brain and 
Behavioral Sciences, University 
of Pavia, Pavia, Italy (I A Cristea)
Correspondence to: 
Dr Ioana A Cristea, Department 
of Brain and Behavioral Sciences, 




The current research agenda for psychological treatments 
recommends moving towards developing interventions 
mechanistically, by translating experimental findings.1 
Cognitive bias modification (CBM) interventions are 
prototypical examples. These encompass a diversity of 
approaches with multiple variants in each, such as 
attention bias modification (ABM), CMB-interpretation 
(CBMI), or approach and avoidance training. Across 
all methods, a target cognitive bias is manipulated, in 
which participants are taught (often without being 
explicitly made aware) to preferentially attend to, process, 
or otherwise engage with specific types of stimuli 
(ie, positive, neutral), while simultaneously avoiding 
others (ie, negative, threatening).2 CBM interventions are 
appealing because of their accessibility and scalability, as 
they consist of brief sessions of a computer-based task, 
possibly administered online.
Nevertheless, the effectiveness of CBM interventions 
is contentious. Meta-analyses of randomised controlled 
trials often reached strikingly different conclusions. For 
the most investigated form—ABM for anxiety disorders—
some meta-analyses reported small, frequently non-
significant, symptom reductions compared with control 
conditions,3,4 whereas others reported significant effects 
of larger magnitude.5,6 There were fewer trials for 
depression, with mixed findings.3,7
The diversity of CBM procedures is mirrored by the 
use of various control groups, rendering the standard for 
gauging the effectiveness of CBM uncertain. For 
instance, because the tasks are computerised, usually not 
requiring participant awareness, several studies have 
used a control condition aimed to function as a placebo. 
This so-called no contingency or sham training control 
task is identical to the active intervention, except that no 
stimulus type is favoured—ie, positive or neutral stimuli 
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Summary
Background Cognitive bias modification (CBM) therapies, including attention bias modification, interpretation bias 
modification, or approach and avoidance training, are prototypical examples of mechanistically derived treatments, 
but their effectiveness is contentious. We aimed to assess the relative effectiveness of various CBM interventions for 
anxious and depressive symptomatology.
Methods For this systematic review and network meta-analysis, we searched PubMed, PsycINFO, Embase, and 
Cochrane Central Register from database inception up until Feb 7, 2020. We included randomised controlled trials of 
CBM versus control conditions or other forms of CBM for adults aged 18 years and older with clinical or subclinical 
anxiety or depression measured with a diagnostic interview or a validated clinical scale. We excluded studies 
comparing CBM with a non-CBM active intervention. Two researchers independently selected studies and evaluated 
risk of bias with the Cochrane Collaboration tool. Primary outcomes encompassed anxiety and depressive symptoms 
measured with validated clinical scales. We computed standardised mean differences (SMDs) with a restricted 
maximum likelihood random effects model. This study is registered with PROSPERO, CRD42018086113.
Findings From 2125 records we selected 85 trials, 65 (n=3897) on anxiety and 20 (n=1116) on depression. In a well 
connected network of anxiety trials, interpretation bias modification outperformed waitlist (SMD –0·55, 95% CI 
–0·91 to –0·19) and sham training (SMD –0·30, –0·50 to –0·10) for the primary outcome. Attention bias modification 
showed benefits only in post-hoc sensitivity analyses excluding post-traumatic stress disorder trials. Prediction 
intervals for all findings were large, including an SMD of 0. Networks of depression trials displayed evidence of 
inconsistency. Only four randomised controlled trials had low risk of bias on all six domains assessed.
Interpretation CBM interventions showed consistent but small benefits; however heterogeneity and risk of bias 
undermine the reliability of these findings. Larger, definitive trials for interpretation bias modification for anxiety 
might be warranted, but insufficient evidence precludes conclusions for depression.
Funding Romanian Ministry of Research and Innovation, The National Council for Scientific Research—The Executive 
Agency for Higher Education, Research, Development and Innovation Funding.
Copyright © 2020 Elsevier Ltd. All rights reserved.
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appear as frequently as negative ones. As with placebo, 
some studies reported benefits for participants randomly 
assigned to this control arm.8 Furthermore, it is unclear 
whether some versions of CBM are more effective than 
others for specific symptoms.
Because of the scarcity of studies comparing versions of 
CBM with each other and with different control groups, 
these questions cannot be settled in a typical pairwise 
meta-analysis of direct comparisons. Network meta-
analyses synthesise direct and indirect evidence, enabling 
the estimation of comparative effects even in the absence 
of trials directly comparing interventions.9
We therefore did a systematic review and network meta-
analysis to establish the relative effectiveness of CBM 
procedures (ie, ABM, CBMI, approach and avoidance 
training), compared with each other and with control 
groups, for anxious and depressive symptomatology.
Methods
Search strategy and selection criteria
For this systematic review and network meta-analysis, 
we searched PubMed, PsycINFO, Embase, and 
Cochrane Central Register of Controlled Trials databases 
from database inception up until Feb 7, 2020, using the 
combinations of terms (both as controlled vocabulary 
thesaurus and free text) relating to “cognitive bias modi-
fication”, “attention* bias modification”, “attention* 
bias training”, “interpret* bias modification”, and 
“anx*”, “fear”, “depress*”, “dysth*”, “obsess*”, “phob*”, 
“panic”, “agoraphob*”, “PTSD”, “post traumatic”, “acute 
stress”, “adjustment disorder” (see appendix p 4 for 
complete search strings). We also inspected references 
from the most recent systematic reviews and meta-
analyses.3,4,10,11 Peer-reviewed publications in Dutch, 
English, German, Italian, Romanian, and Spanish were 
considered.
Eligible studies were randomised controlled trials 
comparing a CBM intervention to a control condition or 
to another form of CBM for anxious or depressive 
symptom outcomes measured on validated clinical scales, 
in adults aged 18 years and older whose primary complaint 
consisted of symptoms of anxiety or depression, either 
diagnosed with a diagnostic interview (eg, structured 
clinical interview for DSM-IV) or a validated clinical scale 
(eg, Liebowitz Social Anxiety Scale), or of subclinical 
intensity evaluated on a validated clinical scale. Partici-
pants with comorbid anxious or depressive symptoms 
were eligible. Disorders were defined according to the 
DSM-IV or DSM-IV-text revised, as recruitment in most 
trials probably predated DSM-5. Combination studies of 
CBM and another intervention were eligible, provided the 
control group also received the ancillary intervention. 
Studies contrasting CBM with non-CBM active inter-
ventions (eg, cognitive behavioural therapy) were 
Research in context
Evidence before this study
We searched PubMed from database inception up to 
Jan 1, 2019, using the search “((cognitive bias) OR (attention* 
bias) OR (interpret* bias) AND (training or modification)) AND 
(anxiety disorder[MeSH Terms] OR anxiety[MeSH Terms] OR 
Trauma and Stressor Related Disorders[MeSH Terms] OR 
depressive disorder[MeSH Terms] OR depression[MeSH Terms]) 
AND (meta-analy*[Title/Abstract])”. No language restrictions 
were imposed. We identified 64 records, of which 12 were 
meta-analyses including cognitive bias modification (CBM) 
interventions for clinically relevant outcomes related to 
depression or anxiety in adults. There was an additional 
overview of meta-analyses. Most meta-analyses focused on 
attention bias modification. For interpretation bias 
modification, the most recent meta-analysis included trials 
done up to 2013 and is probably outdated. Despite this 
proliferation, no clear answers emerged as to whether 
investment in CBM as a treatment is justified and the scientific 
community is polarised about how to move forward. Some 
researchers argue that CBM interventions have at best small 
and transient clinical benefits and hence translation to clinical 
trials has largely been unsuccessful. Yet others focus on more 
substantial benefits for various subgroups and support further 
investment in clinical trials. However, CBM is a heterogeneous 
family of interventions and it is possible that some forms have 
been more successfully translated than others.
Added value of this study
To our knowledge, we report the first network meta-analysis of 
CBM for clinically relevant outcomes, aggregating the largest 
number of trials to date. This methodology has the unique 
advantage of simultaneously drawing from direct and indirect 
comparisons and can therefore answer questions regarding 
relative effectiveness. Our findings across four network 
meta-analyses comprising 85 randomised trials in participants 
with anxious or depressive symptoms showed that one CBM 
intervention—interpretation bias modification—was 
consistently more effective than control conditions for 
symptoms of anxiety and depression in anxiety disorders. 
No reliable conclusions could be drawn for depressive disorders, 
because of inconsistency in the networks likely to be caused by 
the small number of direct comparisons.
Implications of all the available evidence
The notion of developing new treatments mechanistically, 
by identifying targets from experimental laboratory studies 
(ie, experimental psychopathology), is widely embraced as key 
in a programmatic new research agenda. CBM interventions 
represent a structured and consolidated attempt along these 
lines. Interpretation bias modification emerged as a promising 
treatment and could warrant large-scale testing, ensuring 
masking of participants and outcome assessors to avoid 
outcome reporting bias.
See Online for appendix
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excluded. State measures of anxiety or negative mood 
were ineligible because they do not reliably index 
symptoms of clinical importance.
Two researchers (LAF and RG) independently screened 
all abstracts, subsequently examined full texts, and 
selected eligible randomised controlled trials. All disagree-
ments were resolved by discussion and consultation with 
a third author (IAC) until consensus was reached. Protocol 
changes are detailed in the appendix (p 4).
Data extraction
We extracted information about: (1) the sample, including 
clinical (diagnosed) and subclinical (elevated symptoms); 
(2) total number of participants randomly assigned; 
(3) CBM intervention as in approach and avoidance 
training, ABM, CBMI (definitions in table 1); (4) control 
condition, including sham training, opposite ABM, 
waitlist (table 1); (5) number of CBM sessions; (6) delivery, 
including laboratory, home, clinic, or combinations; 
(7) outcome measures for anxiety and depression; and 
(8) publication year.
We expected trials to use multiple outcome measures; 
hence we prespecified a hierarchy. For studies reporting 
both anxiety and depression outcomes, we first 
considered the investigator-declared primary outcome. 
If none was identified, we selected it based on the focus 
of the intervention (eg, anxiety outcomes for anxiety 
disorders). Clinician-based instruments were favoured 
over self-report, if available.
As anxiety and depression have a high likelihood of 
comorbidity,12 we also considered outcomes for comorbid 
depression in trials of CBM for anxiety disorders and 
anxiety in trials of CBM interventions for depressive 
disorders.
We used the risk of bias assessment tool, developed by 
the Cochrane Collaboration,13 which assesses possible 
sources of bias in randomised controlled trials. The 
following domains were rated: random sequence gener-
ation; allocation concealment; masking of partici pants 
and personnel; masking of outcome assessors; incomplete 
outcome data; and selective outcome reporting. Masking 
of participants and personnel was considered low risk if 
masking of participants was attempted, regardless of 
whether subsequent checks were done to establish if it 
was maintained. For masking of outcome assessors, 
clinician-based measures were prioritised. For self-report, 
participants were considered their own assessors,13 with 
ratings of low risk given if they were masked to the 
intervention received. Incomplete outcome data were 
assessed as low risk if all randomly assigned participants 
were included in the analysis, through use of an intention-
to-treat approach or complete data availability. Selective 
outcome reporting was assessed as low risk if primary 
and secondary outcomes were prespecified in a pro-
spectively registered protocol or trial registration, with no 
substantial changes between registration and public ation. 
Retrospectively registered or non-registered studies were 
rated as unclear.
Two independent researchers (LAF, RG) extracted 
outcome data and rated risk of bias, with disagreements 
resolved by consensus after discussion with another 
author (IAC).
Data analysis
Means, SDs, and sample sizes in each group were used 
to calculate between-groups effect sizes as post-inter-
vention standardised mean differences (SMDs) and 
corresponding 95% CIs. The SMD represents the differ-
ence in means between the intervention and control 
groups divided by the pooled SD. Intention-to-treat data 
were preferred, when available. For studies with two or 
more groups from the same category (ie, a type of CBM 
or of control), we extracted data from those most similar 
to the standard version. For example, if a study contained 
both CBMI and a modified version of it with additional 
components, we chose the former. If data were insuf-
ficient for effect size calculations, study authors were 




Participants are instructed to either push a joystick towards the computer screen 
away from themselves to make the presented stimuli smaller and disappear (avoid 
condition), or pull the joystick away from the screen towards themselves to magnify 
the presented stimuli (approach condition)
ABM Participants are typically presented with pairs of words or faces (neutral or 
threatening) and are trained to direct their attention away from the threatening 
stimulus by situating the probe in the position of the neutral or positive word or face 
whenever it was paired with a threatening one; there are many variations in terms of 
stimuli type (eg, faces, words, other images), and the timing and location of their 
presentation, as well as tasks used for training, (eg, dot-probe, visual search task)
ABM and CBMI A combination of ABM and CBMI, usually delivered in the same session
CBMI Participants are typically presented with ambiguous situations (often realistic 
scenarios capturing situations occurring in daily life) and are trained to resolve them 
to favour neutral or positive interpretations over negative interpretations; most 
CBMI paradigms target the broad range of disorder-relevant situations and 
cognitions, although some have a very specific focus (eg, interpretations of one 
specific kind of situation or behaviour)
Opposite ABM The same as ABM, except that participants are trained to direct their attention 
toward the threatening stimulus
Opposite CBMI The same as CBMI, except that participants are trained to resolve the ambiguous 
situations to favour negative interpretations
Sham training for 
approach and 
avoidance training
Typically, the same as approach and avoidance training, except that there is no 
contingency between pushing or pulling the joystick and the emotional valence of 
the stimuli, or the stimuli have no emotional valence
Sham training for 
ABM
Typically, the same as ABM, except that there is no contingency between probe 
location and the presented stimuli: in 50% of trials the probe replaces neutral or 
positive words or faces and in 50% of trials the probe replaces negative words or 
faces
Sham training for 
CBMI
Typically, the same as CBMI, except that the ambiguous situations are not 
consistently positively resolved (how exactly this is operationalised varies, but often 
an ambiguous scenario is resolved to favour positive or benign interpretations in 
one half of the trial and negative interpretations in the other half); or the ambiguous 
situations have no emotional valence for the participants
Waitlist Participants are assigned to a waitlist for the duration of the study and offered the 
intervention after the active treatment group
ABM=attention bias modification. CBMI=cognitive bias modification-interpretation.
Table 1: Description of typical cognitive bias modification interventions and control conditions
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meta-analysis with a restricted maximum likelihood 
estimator to do four network meta-analyses (one per 
outcome). We graphically represented results as network 
plots, whereby the size of the nodes is directly 
proportional to the number of patients, while the 
thickness of the lines connecting the nodes is weighted 
by the number of trials directly assessing the comparison. 
Additionally, we constructed network plots that incor-
porated risk of bias for each domain rated, using coloured 
edges to represent low, high, and unclear risk of bias. 
The comparison-specific bias level was set as the rating 
in most studies in each comparison (ie, the mode).14
The transitivity assumption was evaluated by visually 
inspecting relevant study characteristics. On the basis of 
previous literature, we considered two potential effect 
modifiers (number of sessions and delivery setting) 
and examined their distributions across comparisons. 
Network consistency, the extent to which included 
studies are comparable, both statistically and substan-
tively,15 was evaluated with three methods. First, to detect 
significant overall inconsistency, we used a design-by-
treatment interaction model with a global Wald statistic, 
which under consistency follows a χ² distribution.16–18 
Non-significant p values indicate no inconsistency. 
Second, we used a loop-specific approach to estimate the 
inconsistency factor in each loop as the absolute 
difference between direct and indirect estimates and 
truncating the CIs to 0, using a Z-test to decide if 
inconsistency was significant19 (ie, the lower limit of the 
inconsistency factor’s 95% CI touches 0). Thirdly, we 
used a side-splitting method,16 a frequentist adaptation of 
the original hierarchical Bayesian method.18,20 It reports 
the estimated direct and indirect treatment effects and 
their difference, with consistency inferred based on the 
p value for the difference.
Contribution plots displayed the differential contri-
butions of direct comparisons to the network summary 
effect. Interventions were ranked by calculating the 
surface under the cumulative ranking (SUCRA), which 
denotes the probability (in percentages) of superior 
effectiveness for each intervention compared with a 
theoretical ideal (ie, always the best without uncertainty) 
intervention.
Heterogeneity was investigated by displaying forest 
plots, including summary effects along with their 
95% CIs and their corresponding 95% prediction intervals 
for all comparisons. Prediction intervals represent CIs of 
the approximate predictive distribution of the future trial, 
considering heterogeneity.21 We did three further sensi-
tivity analyses excluding studies: (1) using approach and 
avoidance training, initially devised for addiction22; (2) on 
participants with post-traumatic stress disorder, in which 
better outcomes were reported for sham than for ABM23; 
and (3) in which participants in the sham intervention 
were not exposed to any contingency (eg, neutral scen-
arios). We used network restricted maximum likelihood 
meta-regression24 with mvmeta to examine two possible 
moderators for the comparison between CBM and 
sham—number of treatment sessions (continuous) and 
delivery setting (recoded dichotomously as laboratory vs 
others).
Small study effects were examined through visuali-
sation of comparison-adjusted funnel plots and with 
Egger’s linear regression test of funnel plot asymmetry.25 
Interventions were ordered such that all active inter-
ventions were contrasted sequentially to waitlist, sham, 
and opposite ABM control conditions.14
All analyses were done in STATA/SE version 1526 
(network and mvmeta14,16,24) and R27 (netmeta28). The meta-
analysis was prospectively registered with PROSPERO, 
CRD42018086113, and reported following the Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses extension for network meta-analyses.29
Role of the funding source
The funder of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author 
had full access to all the data in the study and had 
final responsibility for the decision to submit for 
publication.
Figure 1: Study selection
1156 records screened
302 full-text articles assessed for eligibility 
82 reports (85 trials) included in the network meta-analysis
2125 records identified through database 
searching 
969 duplicates removed
0 additional records identified through 
other sources  





1 unclear if clinical or subclinical symptoms are present
1 no clear inclusion criteria or recruitment from general 
psychiatric population
81 unselected participants (no clinical or subclinical 
symptoms)
26 no comparison of interest
45 only state anxiety outcomes, no anxiety or depression 
outcomes 
1 pooled results only (anxious and non-anxious)
7 no effect size data available
2 no full-text available
15 secondary report
854 records excluded based on title or abstract 
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Results
The search generated 2125 records (1156 after duplicate 
removal). We excluded 854 records based on abstract 
inspection, and examined 302 full texts. The PRISMA 
flowchart30 (figure 1) shows the inclusion process and the 
appendix (pp 12–21) reports the studies excluded with 
reasons. We contacted authors of eight studies with 
insufficient effect size data and retrieved datasets for one. 
Consequently, 82 reports describing 85 separate trials 
were included in the network meta-analysis.
Detailed characteristics of included studies are described 
in the appendix (pp 22–30). 65 trials (n=2026 treated and 
n=1871 control participants) focused on anxiety-related 
disorders of clinical or subclinical intensity. 20 trials 
(n=544 treated and n=572 control participants) focused on 
depressive disorders or symptoms. Delivery settings 
included the laboratory (n=44 studies), online or at home 
(n=21), clinic or hospital (n=8), or a combination of these 
(n=12). Treatment sessions ranged from one to 84, with 
12 randomised controlled trials using one session, and 
43 randomised controlled trials using eight sessions or 
more. Most trials used sham training and directly 
compared ABM and sham (figure 2). Comorbid depression 
outcomes were reported in 31 studies (n=1101 treated and 
n=1070 control participants) on anxiety disorders. 
Conversely, comorbid anxiety outcomes were present in 
11 studies on depressive disorders (n=250 treated and 
n=251 control participants).
For the primary outcome of anxiety, the network plot 
(figure 2A) showed a well connected network, consisting 
of eight nodes (appendix p 51 for contribution plot). Most 
direct comparisons were at unclear risk of bias, except 
for blinding of outcome assessment (unclear or high) 
and incomplete outcome data (low; appendix p 52). 
Across methods, there was no evidence for inconsistency 
(appendix pp 10, 34, 53). In the network meta-analysis 
(table 2, appendix p 54), only CBMI significantly reduced 
anxiety compared with waitlist (SMD –0·55, 95% CI 
–0·91 to –0·19) or sham (SMD –0·30, –0·50 to –0·10). 
However, prediction intervals for these comparisons 
were large and included 0. SUCRA probabilities indicated 
that approach and avoidance training and CBMI 
presented the greatest likelihood of reducing anxiety 
outcomes (both around 77%; appendix p 55). Egger’s test 
did not detect funnel plot asymmetry (t[80] 0·31; p=0·76; 
appendix p 56).
For the primary depression outcome, the network plot 
(figure 2B) shows a well connected network of CBM 
interventions, except for the ABM and CBMI combi-
nation. Across all methods, there was evidence for 
inconsistency (appendix pp 10, 35, 57). Risk of bias, the 
contribution plot, and SUCRA probabilities are presented 
in the appendix (pp 58–60). In the network meta-analysis 
(table 3, appendix p 61), CBMI significantly reduced 
depression compared with waitlist (SMD –0·63, 95% CI 
–1·04 to –0·23). The 95% prediction intervals were large 
and included 0 (appendix p 61). Other significant 
differences involved the singly connected ABM and 
CBMI node (appendix p 10). Egger’s test detected funnel 
plot asymmetry (t[22] –2·10; p=0·047; appendix p 62).
For the secondary outcome of comorbid depression (in 
anxiety randomised controlled trials), the network plot 
(figure 2C) showed a well connected network of CBM 
interventions, consisting of six nodes. None of the 
methods revealed evidence of inconsistency (appendix 
pp 10, 36, 63). Risk of bias, the contribution plot, and 
SUCRA probabilities are displayed in the appendix 
(pp 64–66). In the network meta-analysis (appendix 
pp 37, 67), only CBMI significantly reduced depression 
compared with waitlist (SMD –0·42, 95% CI 
–0·68 to –0·15), sham (SMD –0·21, –0·41 to –0·01), and 
ABM (SMD –0·24, –0·46 to –0·01). However, all 95% 
prediction intervals were large and, except for CBMI 
versus waitlist, included 0. Egger’s test did not detect 
funnel plot asymmetry (t[42] –1·34; p=0·19; appendix p 68).
For the secondary outcome of comorbid anxiety in 
depression randomised controlled trials, the network 
plot (figure 2D) evidenced a well connected network of 
CBM interventions, consisting of four nodes. Most 
comparisons were at unclear and high risk of bias 
(appendix p 69). Evidence for inconsistency was mixed, 
with two of the three methods indicating inconsistency 
(appendix pp 10, 38, 70). The contribution plot and 
SUCRA probabilities are displayed in the appendix 
(pp 71–72). The network meta-analysis showed no 
Figure 2: Network geometry of CBM interventions
Outcomes are shown for anxiety (A), depression (B), comorbid depression (C), and comorbid anxiety (D). The size 
of the nodes is directly proportional to the number of patients, while the thickness of the lines connecting the 
nodes is weighted by the number of trials directly assessing the comparison. AAT=approach and avoidance 
training. ABM=attention bias modification. CBMI=cognitive bias modification-interpretation. OABM=opposite 
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significant differences (appendix pp 39, 73). Egger’s test 
did not detect funnel plot asymmetry (t[11] 0·74; p=0·47; 
appendix p 74).
Most trials had uncertain or high risk of bias for five of 
six domains (appendix pp 31, 50). Four randomised 
controlled trials had low risk of bias for all domains, 
while six randomised controlled trials had low risk for 
five domains. Sequence generation was rated low risk in 
31 trials (42 had insufficient information), allocation 
concealment in 13 trials (67 insufficient information), 
and masking of participants and personnel in 37 trials 
(38 unclear). Masking of outcome assessors was rated 
low risk in 39 trials (69 used self-report measures 
exclusively). For incomplete outcome data, 54 studies 
reported intention-to-treat analyses or complete outcome 
data were available. For selective outcome reporting, 
12 studies were rated low risk.
Post-hoc sensitivity analyses closely replicated the main 
analyses (appendix pp 10–11), with a few differences. With 
the exclusion of post-traumatic stress disorder trials (n=7), 
ABM significantly reduced anxiety compared with wait-
list (SMD –0·35, 95% CI –0·59 to –0·12) and sham 
(SMD –0·16, –0·28 to –0·04). Excluding trials where sham 
participants were not exposed to any contingency (n=15), 
CBMI significantly reduced anxiety compared with waitlist 
(SMD –0·62, 95% CI –1·07 to –0·18), but not sham.
Meta-regression analyses showed that the number of 
treatment sessions was not significantly related to out-
comes (appendix p 48). Delivery setting was a significant 
moderator only for the ABM versus sham comparison 
(β=0·44, 95% CI 0·10–0·77) for anxiety outcomes 
(appendix p 49).
Discussion
In a network meta-analysis of 85 trials, CBM interventions 
showed few benefits over control conditions, for both 
anxious and depressive symptomatology. In 65 trials in 
participants with anxiety, CBMI outperformed waitlist 
(SMD –0·55, 95% CI –0·91 to –0·19) or sham training 
(SMD –0·30, –0·50 to –0·10) for anxiety outcomes. 
However, prediction intervals were large and contained 
an SMD of 0, suggesting that the effects of future similar 
trials could fluctuate across a wide range of effects. 
Similar results were reported for comorbid depression 
outcomes, present in around half of the trials, suggesting 
that the effects of CBMI might be disorder-specific rather 
than symptom-specific. These effects are modest com-
pared with similarly delivered internet-based cognitive 
behavioural interventions for anxiety disorders (SMDs 
compared with mostly waitlist control ranging from 0·70 
for generalised anxiety disorder to 1·31 for panic 
disorder).31 In post-hoc analyses excluding the more inert 
type of sham (neutral scenarios), only differences 
between CBMI and waitlist remained significant. Few 
differences emerged among CBM interventions, except 
for the superiority of CBMI over ABM for comorbid 
depression.
For ABM, the only significant findings consisted of 
small effects compared with waitlist and sham on primary 
anxiety outcomes, in sensitivity analyses excluding post-
traumatic stress disorder trials. Our definition of anxiety 
AAT ABM ABM and CBMI CBMI Opposite ABM Opposite CBMI Sham
ABM –0·46 
(–1·50 to 0·58)
·· ·· ·· ·· ·· ··
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Data are standardised mean differences and 95% CIs. Negative values favour the intervention in the column, positive values the intervention in the row. AAT=approach and 
avoidance training. ABM=attention bias modification. CBMI=cognitive bias modification-interpretation. *Significant standardised mean differences.
Table 2: Relative treatment effects for all possible pairwise comparisons estimated in the network meta-analysis for anxiety outcomes
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Data are standardised mean differences and 95% CIs. Negative values favour the intervention in the column, positive 
values the intervention in the row. ABM=attention bias modification. CBMI=cognitive bias modification-
interpretation. *Significant standardised mean differences.
Table 3: Relative treatment effects for all possible pairwise comparisons estimated in the network meta-
analysis for depression outcomes
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disorders predated the DSM-5, hence included stress-
related disorders (all included post-traumatic stress 
disorder trials relied on the DSM-IV-text revised). More 
generally, findings for ABM corroborate previous meta-
analyses reporting very similar estimates,3,4 but contradict 
others reporting larger effects of ABM for participants 
with clinical anxiety.5,6 A pairwise meta-analysis of 
11 studies5 showed moderate effects of ABM for clinician-
rated (SMD 0·42, 95% CI 0·18–0·66), but not self-
reported, anxiety. In an individual participant data 
meta-analysis of 13 trials,6 the authors reported significant 
effects of ABM on diagnostic remission (odds ratio 2·57, 
95% CI 1·31–5·22), but not on the continuous measure, 
clinician-administered Liebowitz Social Anxiety Scale. 
Laboratory delivery was associated with better outcomes 
for ABM versus sham, corroborating previous reports.3,4
In the considerably fewer trials on participants with 
depression (n=20 trials), only CBMI outperformed waitlist 
for primary depression outcomes (SMD –0·63, 95% CI 
–1·04 to –0·23). However, because of evidence of network 
inconsistency, this finding might be unreliable. The 
network geometry revealed one open, singly connected, 
node for the ABM and CBMI com bination. Aside from a 
direct comparison with sham, the whole evidence for the 
combined intervention was indirect, rendering the very 
large effects observed not credible. Hence, the effective-
ness of the combined treatment cannot be established. We 
used a hierarchy of outcomes, favouring the investigator-
declared primary outcomes and, barring that, clinician-
based over self-report measures. Therefore, it is unlikely 
that our findings are explained by the choice of measures. 
Importantly, anxiety trials formed well connected 
networks for both anxiety and depression outcomes, with 
no evidence for inconsistency, making fundamental 
differences between trials unlikely and further supporting 
the robustness of the findings.
Few differences emerged among the various control 
conditions used. Waitlist was always nominally inferior to 
sham CBM, supporting the notion that interventions 
should be compared with more adequate, active control 
groups.32 By contrast, a strength of CBM trials is the 
frequent inclusion of a sham condition, in which partici-
pants are not encouraged to preferentially process a 
specific stimulus type. Analogous to pill placebo, these 
active control conditions can be targeted (50:50 ratio of 
targeted vs non-targeted emotional stimuli) or just consist 
of neutral stimuli. Attempts to mask participants to their 
group allocations contribute to rendering the sham 
condition similar to placebo, a rare occurrence in research 
on psychological interventions. Yet just less than half of 
the trials specifically mentioned participant masking, 
with an almost equal number lacking information. 
Therefore, it is difficult to ascertain whether the sham 
condition truly remained as such. In post-hoc sensitivity 
analyses excluding studies using the neutral version of 
sham as control, CBMI was only superior to waitlist. 
Finally, although sham training does not ostensibly 
encourage preferential processing, it might nonetheless 
have beneficial emotional effects33 by repeatedly exposing 
participants to bias contingencies and enhancing, for 
example, psychological flexibility.34 Nonetheless, pill 
placebo is also often not inert.33 Further more, some trials 
included a seemingly paradoxical opposite intervention 
(ie, opposite ABM), in which contingencies are modified 
so that negative stimuli are preferentially attended to or 
processed, in an effort to increase cognitive bias. If the 
relationship between attention bias and anxiety symptoms 
is, as hypothesised,2 causal, this control intervention 
could be expected to be deleterious, similarly to a nocebo 
(ie, when a patient’s negative expectations result in a 
more negative effect). Opposite ABM did not diverge 
from other control conditions; however, because of ethical 
reasons, few trials used this method.
Our network meta-analysis is not without limitations. 
For most trials, owing to insufficient information, risk of 
bias was rated as uncertain across several of the domains 
considered. The minuscule number of studies with low 
overall risk precluded us from running further sensitivity 
analyses. The conduct and reporting of trials of CBM 
interventions is still wanting, as previously shown.3 
Consequently, as high or unclear risk of bias was 
associated with exaggerated effect estimates across 
interventions,35 the effects reported might overestimate 
the true effects. Other methods of assessing evidential 
value36,37 might complement a more in-depth assessment 
of trials with uncertain risk. We found little statistical 
evidence of small study effects in any network. However, 
publication bias cannot be completely ruled out without 
directly identifying unpublished trials. We excluded trials 
in the grey literature such as dissertations and conference 
proceedings, owing to concerns about insufficient data 
reporting and reliably connecting these reports with 
journal articles. For individuals with depression, trials 
were few and there was evidence of inconsistency in 
the resultant networks, meaning findings might be 
unreliable.
As commonly seen in psychological treatment research, 
heterogeneity is unavoidable. Both ABM and CBMI 
denote families of approaches targeting a particular 
process, with variations in the tasks and stimuli used, 
additional components, and doses. Heterogeneity extends 
to control conditions, particularly sham training, though 
most studies used the no contingency (ie, 50:50 ratio) 
group. For the purposes of the network meta-analysis, 
sham training conditions were also considered inter-
changeable across CBM interventions. Although their 
principle is the same (ie, participants are not encouraged 
to preferentially process a specific stimulus type), there is 
variation in the nature of the stimuli (eg, faces in ABM, 
scenarios in CBMI) or tasks (eg, dot-probe in ABM, 
ambiguous situations in CBMI) used. We used the 
random effects model to account for the expected clinical 
and methodo logical heterogeneity and we observed no 
evidence to contradict our assumption in terms of 
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heterogeneity and inconsistency. Moreover, CBM tasks 
might differ in reliability and effect on targeted bias. We 
only investigated two study-level moderators, as, for a 
meaningful investi gation of participant-level moderators, 
individual partici pant data would have been required.38
The current network meta-analysis aggregates the 
largest number of CBM trials to date, to our knowledge, 
and has the unique methodological advantage of simul-
tan eously drawing from direct and indirect comparisons. 
CBMI emerged as promising and could warrant large-
scale testing, ensuring masking of participants and of 
outcome assessors and avoiding outcome reporting bias. 
Future trials would also need to clarify whether the 
intervention should be implemented as stand-alone or 
added to another, and whether it is cost-effective, given 
modest benefits observed so far.
CBMI could be construed as a schematic form of 
cognitive restructuring and it is unclear whether it deals 
with modifying an actual bias (ie, implicitly) or, rather, 
prompts participants to explicitly use cognitive restruc-
turing, a core strategy in most cognitive behavioural 
approaches. Conversely, owing to the already large 
number of trials and observed small effects, it is doubtful 
whether further investment in the current dominant 
ABM paradigms as treatment is justified. This approach 
might only merit further experimentation in restricted 
settings with well specified groups of individuals, at least 
until rigorous, pre-registered pre-clinical studies have 
tested the reliability and benefits of alternative ABM 
paradigms.
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